From the Test Tube to the Treatment Room: Fundamentals of Boron-containing Compounds and their Relevance to Dermatology

James Q. Del Rosso, DO, FAOCD, Clinical Professor (Dermatology Adjunct Faculty), Touro University College of Osteopathic Medicine, Henderson, Nevada; Private Dermatology Practice, Las Vegas Skin & Cancer Clinics/West Dermatology Group, Las Vegas and Hernderson, Nevad; Jacob J. Plattner, PhD, Senior Vice President of Research, Anacor Pharmaceuticals, Palo Alto, California

Disclosure: Dr. James Q. Del Rosso is a dermatologist in private practice in Henderson, Nevada. He is the primary and predominant author of this article along with authorship assistance and contribution from Dr. Jacob J. Plattner (see disclosure below). Dr. Lee Zane, a dermatologist who is employed as Senior Vice President of Clinical Development and Chief Medical Officer at Anacor Pharmaceuticals, assisted in review of the article for accuracy of scientific content and proofreading prior to submission to the journal. After submission to the journal, Dr. Del Rosso served as the sole contact during peer review, responses to queries, and finalization of article content. No other individuals, including medical writers from any companies or agencies, participated in the development of article content, in any decisions pertaining to inclusion or exclusion of information, or in the authorship of this article. Dr. Del Rosso serves as a consultant to Anacor Pharmaceuticals, a company that is developing boron-based molecules, including his involvement with the development and authorship of this article. Dr. Del Rosso receives compensation for performance of consultative activities for Anacor Pharmaceuticals. He also has served as a consultant, advisory board participant, clinical investigator, and speaker and is currently active in some or all of these roles for Allergan, Aqua, Bayer (Dermatology), Dermira, Ferndale, Galderma, LeoPharma, Medicis (division of Valeant), Merz, Onset Dermatologics, Promius, PuraCap, Quinnova, Ranbaxy, Taro Pharmaceuticals, Unilever, Valeant (Consumer Products), and until recently Warner-Chilcott (now Actavis). Relatively recent affiliations that are no longer active are Eisai, Stiefel (a GSK Company), and TriaBeauty. Dr. Jacob J. Plattner is a research scientist at Anacor Pharmaceuticals where he holds the position of Senior Vice President of Research.

The development of new drug classes and novel molecules that are brought to the marketplace has been a formidable challenge, especially for dermatologic drugs. The relative absence of new classes of antimicrobial agents is also readily apparent. Several barriers account for slow drug development, including regulatory changes, added study requirements, commercial pressures to bring drugs to market quickly by developing new generations of established compounds, and the greater potential for failure and higher financial risk when researching new drug classes. In addition, the return on investment is usually much lower with dermatologic drugs as compared to the potential revenue from “blockbuster” drugs for cardiovascular or gastrointestinal disease, hypercholesterolemia, and mood disorders. Nevertheless, some researchers are investigating new therapeutic platforms, one of which is boron-containing compounds. Boron-containing compounds offer a wide variety of potential applications in dermatology due to their unique physical and chemical properties, with several in formal phases of development. Tavaborole, a benzoxaborole compound, has been submitted to the United States Food and Drug Administration for approval for treatment of onychomycosis. This article provides a thorough overview of the history of boron-based compounds in medicine, their scientific rationale, physiochemical and pharmacologic properties, and modes of actions including therapeutic targets. A section dedicated to boron-based compounds in development for treatment of various skin disorders is also included. (J Clin Aesthet Dermatol. 2014;7(2):13–21.)

The lifeline of any medical discipline is the continued development of diagnostic tools and treatment approaches that improve therapeutic outcomes and the quality of life of affected patients. In the field of dermatology, where profits from new drug development are substantially lower than in other medical areas (i.e., cardiovascular disease, gastrointestinal disease, mood disorders), this lifeline must be sustained through continued commitment to quality research within large pharmaceutical companies, emerging smaller companies, academic centers, and from others who have the capacity to contribute to advances in clinically relevant research. In drug development, it is important that newer approaches provide true advantages over existing therapies, such as greater efficacy, more favorable safety profiles, improved pharmacokinetic characteristics, shorter durations of therapy, and lower potential for relapse. With topical therapies, tolerability, ease of application, and subjective assessment of the physical characteristics of the vehicle are also very important factors.

Unfortunately, the development of new drug compounds in dermatology has been relatively stagnant, especially with topical therapies and systemic agents other than biologics.[1,2] Three major contributing factors are the increased number and types of studies required during drug development, required changes in study designs, and challenges in defining quantitative endpoints that translate to clinical relevance, especially in some areas of dermatology research.[1] Other factors are limited knowledge of pathophysiology with many skin diseases, risk-benefit ratio considerations with many common skin diseases, increased generic drug intrusion, and the potential for return on investment.[1]

New Topical Compounds in Dermatology
From 1995 through November 2013, among the 37 new topical dermatologic products approved by the United States (US) Food and Drug administration (FDA), less than one-third (11) comprised new active ingredients.[2] These included topical retinoids (adapalene, tazarotene), calcineurin inhibitors (pimecrolimus), antifungal agents (luliconazole, butenafine), agents for rosacea (azelaic acid, brimonidine), and one agent for actinic keratosis (ingenol mebutate). Only one was a topical antibiotic (retapamulin). The remainder of the products in the topical therapy market were predominantly new vehicle formulations, combination therapy products, topical devices (501K-approved products), and a few older systemic compounds that were submitted later for FDA approval as topical products (i.e., tacrolimus, dapsone, mechlorethamine).[2] In a nutshell, most of the new topical products in dermatology over the past several years have been established compounds in new formulations, combination products, topical device (501K) products, or structural analogs of already existing compounds that often provide little or no therapeutic benefit as compared to their predecessor. Nevertheless, it is important to state that some of these new products, despite the absence of a new and novel compound as the active ingredient, may offer some definite advantages as compared to other available products within the same therapeutic class.

New systemic compounds in dermatology. The release into the US marketplace of new FDA-approved systemic compounds administered orally or parenterally has been dominated by oncologic drugs (i.e., metastatic melanoma, basal cell carcinoma) and biologic agents used for psoriasis. Interestingly, many of the more recent major advances in systemic therapies introduced for dermatologic indications (primarily psoriasis) have been biologic agents administered by injection, and more are on the near-horizon. There has clearly been a conspicuous absence of newer oral therapy compounds in dermatology, with examples of more novel oral agents used commonly in dermatology being FDA approved 17 to 25+ years ago (i.e., acitretin [1997], cyclosporine [1995], acyclovir [1985], isotretinoin [1982]).[2–8] With the recent FDA recommendation that oral ketoconazole not be utilized for superficial cutaneous fungal infections due to safety concerns (hepatotoxicity), the armamentarium of oral antifungal agents used in dermatology has remained unchanged for more than two decades.[9,10] With regard to novel oral antibiotic development, only four new antibiotic classes have come to fruition since the early 1960s, most with limited impact.[3] In dermatology, other than penicillin derivatives, cephalosporins, and macrolides, the relative absence of new antibiotic compounds in the United States is exemplified by the fact that the more recent antibiotic classes that encompass agents that are sometimes used in dermatology in the United States are azalides (azithromycin [FDA approval 1991]), third-generation cephalosporins (cefdinir [FDA-approval 1997]), and, less commonly, quinolones (ciprofloxacin [FDA approval 1987]) and oxazolidinones (linezolid [FDA approval 2000]).[11]

Development of antimicrobial compounds. The limited development of new antimicrobial compounds has received widespread attention in the media and in publications within the medical, governmental, and lay public communities. This is especially due to the global emergence of multiresistant pathogens, especially bacteria, with increasing rates of antimicrobial resistance proving to be a very relevant clinical concern with both hospital-acquired and community-acquired infections.[3,11–14] Over time, fewer antibiotics are receiving FDA approval, with a conspicuous absence of new oral antibiotic classes or novel new-generation compounds available in dermatology. Within the more than $30 billion global antibiotic marketplace, most new antibiotics are based on structural modifications made to an antibiotic from a previous generation within the same antibiotic class (i.e., penicillin, cephalosporins, quinolones), an approach that is more expeditious and less complex than researching directions that require more time, effort, and financial support.[3,11,15] Development of systemic and topical antifungal compounds have also been relatively limited. In fact, the expansion of the topical antifungal category has primarily been through the addition of additional compounds within structural classes that already exist or with slight modification (i.e., imidazoles, allylamines, benzylamines) or new vehicle formulations.

New directions in drug development. Despite the challenges and realities that have seemed to retard the number of new drug compounds that are successfully developed and obtain FDA approval, there are continued efforts to develop new compounds and therapeutic classes. More attention is being placed on developing agents from a variety of organic, semi-synthetic, and synthetic sources (“scaffolds”) that have not received adequate attention regarding their drug development potential and not simply through modifications of parent chemical moieties within drug classes that are already available.[3] In some cases, researchers have directed their focus on areas of drug development that have been overlooked or where research has waned despite previous success.

Boron-based molecules in drug development. One category of compounds that has been relatively ignored for several years, and has received considerable attention more recently in drug development research, is boron-containing molecules.[16] There are a few reasons why researchers in pharmaceutical development have overlooked integrating boron into small molecules during chemical modification planning and drug screening. First, is the erroneous perception that incorporation of boron induces toxicity, a notion which has since been refuted by a good body of evidence.[16,17] Notably, boron is found in high concentrations in many natural foods (fruits, nuts, vegetables) and is commonly ingested daily by humans (0.3–4.2mg/day).[16] To add, boric acid, a major metabolite of the boronic acid functional group used in many boron-containing molecules, exhibits a favorable safety profile. Oral lethal dose (LD50) testing in rats shows that boric acid and table salt have very similar LD50 values (2660mg/kg and 3000mg/kg, respectively), and boric acid is a commonly used preservative in ophthalmological and vaginal products and is a major ingredient in a semi-solid squeezable toy for children.[16] To add, genetic toxicology studies have been completed with testing of four benzoxaboroles and one boronic acid ester, all five of which are currently in different phases of human drug development in preparation for FDA submission. All five boron-based molecules demonstrated no genetic toxicology liabilities, thus providing further evidence to support that many boron-based medicinal agents demonstrate favorable safety profiles to date.[17] A second reason relates to previous synthetic chemistry difficulties medicinal chemists encountered integrating boron into small molecules, a challenge that has been overcome by the introduction of new catalysts and other advances in synthetic organoboron chemistry.[16,17] Additional explanations regarding challenges to the incorporation of boron during drug development were related to manufacturing problems with diazoborine molecules. Finally, the over-reactivity/chemical instability of aliphatic boronic acid compounds also presented discovery and developmental challenges. Specifically, prior to the development of methods to alter interactive properties and stability characteristics, integration of boron into certain molecules was fraught with difficulties including a propensity to interact with moieties remote from the therapeutic target site (off-target binding) and/or susceptibility to oxidation and chemical degradation (deborination) with loss of biologic activity.[16,17]

Nevertheless, some researchers noted important advantages that boron can provide as opposed to other atoms (i.e., nitrogen) when completing the process of molecular modification during drug synthesis. Molecular chemists modify molecules to augment or diminish specific properties observed with parent and sister molecules during the course of initial testing of pharmacological and pharmacodynamic properties. Integration of boron into the chemical structure has proven to be very helpful in producing agents that can bind and trap important functional groups involved in key pathophysiological pathways, especially target sites on specific enzymes.[16,18–20] New catalysts and novel methods to integrate boron into various organic molecules have expedited and expanded the development of new boron-containing compounds. The last decade has seen an emergence of several boron-containing molecules in drug development, with boron incorporated into most small molecules as a boronic acid group.[16,17] Various structural modifications related to how boron is integrated produces different structural classes of born-based molecules, with changes in specific physiochemical and pharmacological properties related to alterations in chemical structure.[16–24] The physiochemical and structural characteristics of boron that allow for its versatility and broad range of applications in medicinal chemistry and provide its capacity to trap key functional moieties leading to inhibition of important enzymes and other molecules are reviewed in Table 1.

The objective of this article is to introduce to the dermatological community an overview of the history of boron integration into drug development and explain the fundamental concepts that support relevant modes of action and clinical applications, including for dermatological disorders. Several boron-based molecules are in both early and later development stages including many for dermatological disorders, such as fungal infections, psoriasis, atopic dermatitis, and bacterial infections (Figure 1). Although the explanations here that pertain to organoboron medicinal chemistry may be a bit challenging for clinicians, most of whom may be far removed from benchtop chemistry research, an overall understanding of the general principles that relate to the modes of action of boron-based compounds will accelerate the ability to comprehend how these agents can be applied in the clinical setting when treating patients.

At this point, the two obvious questions about the role of boron in drug development are, “What does boron actually do from a therapeutic standpoint?” and “What is its mode of action as a therapeutic agent?” To properly address these questions, the first step is to recognize that incorporation of boron into a chemical compound is not related to one specific mechanism of action that boron provides. Rather, the physical, chemical, and structural properties unique to boron can often enhance specific activities of many different small molecules that cover a broad range of pharmacological modes of action, pharmacodynamic properties, and pharmacokinetic characteristics.[16–20] Ultimately, the potential therapeutic activity and clinical application of a given boron-containing compound depends on its target as boron serves within a given molecule to promote mimetic activity whereby there is adduct formation upon binding to a specific target site, usually within a key functional enzyme involved either directly or indirectly with important disease-related activity. This binding impairs the function of that target enzyme by trapping a binding site that normally plays a vital pathogenic role and rendering it inaccessible. There are different classes of boron-containing compounds with diverse activity profiles and structure-activity relationships (SARs), with each directing its binding activity at a defined therapeutic target site involved with a specific disease state.[16–20] Therefore, there is potential for therapeutic application of boron-containing compounds in a wide variety of disease states, as a diverse group of therapeutic targets may be inhibited by individual boron-based compounds. Figure 2 shows selected boron-containing molecules and their respective therapeutic targets, all of which play major pathophysiological roles in specific disease states.

Historical Overview of Boron-Containing Compounds Used for Medicinal Purposes
A detailed account of the history of organoboron medicinal chemistry, the development of boron-containing small molecule SARs analysis, and the therapeutic applications of individual boron-based molecules is beyond the scope of this article and is reviewed in detail elsewhere.[16–24] However, some major developments that have occurred over time demonstrate the broad range of advances in organoboron medicinal chemistry and the wide variety of potential therapeutic applications that boron-based molecules can provide. The main categories of boron-containing molecules that have emerged from medical chemistry research are the diazoborines, boronic acid enzyme inhibitors, and benzoxaborole derivatives.[16,17] Figure 1 shows a timeline of some benzoxaborole-based small molecules that are currently in different phases of formal human drug development. Figure 2 depicts clinically relevant examples of boronic acid and diazoborine-based compounds.

Diazoborines. One of the earliest classes of boron-based compounds is the diazaborines, which were synthesized approximately five decades ago; however, the first publications describing their mechanisms of action and antimicrobial properties appeared in 1971.[16,25] This led to a research platform of diazoborine compounds that demonstrated activity against Gram-negative bacteria and Mycobacterium tuberculosis by targeting a specific enzyme (enoyl reductase [ENR]) involved in fatty acid biosynthesis.[16] Other diazoborine compounds based on activities evaluated to date include estrogen-like compounds.[16] Chemical manufacturing and control challenges can complicate the production of diazoborine compounds.

Boronic acid enzyme inhibitors. Boron-based compounds that incorporate boronic acid or a boronic functional group comprise many of the boron-based compounds that are being evaluated in drug development projects.[16,17] A major challenge with aliphatic boronic acid enzyme inhibitors is off target binding, which reduces their selectivity and potential effectiveness as therapeutic agents.[16,17] This adverse property, which is known to occur with this category of boron-based compounds, is due to their high level of chemical reactivity.

Boronic acid enzyme inhibitors have been developed that exert potent activity against key target sites on serine protease (SP) enzymes. In addition, boronic compounds inhibiting other enzymes are being pursued that target a variety of cutaneous infections and other disease states.16 Examples are listed in Table 2.

The first therapeutic proteasome inhibitor to be tested in humans and now commercialized was bortezomib (Velcade, Millennium Pharmaceuticals, Inc.), a boronic acid-containing molecule FDA approved for treatment of relapsed multiple myeloma and mantle cell lymphoma.[16] The boron atom in bortezomib binds the catalytic site of the 26S proteasome with high affinity and specificity, with some patients demonstrating a highly favorable therapeutic response. Toxicities associated with botezomib temporarily dampened enthusiasm for further development of boron-based compounds; however, it was later determined that specific toxic effects were mechanism of action related and not due specifically to the presence of boron, and a second company providing bortezomib had manufactured some lots of the product with excessive amounts of the active compound above the acceptable range allowed based on the FDA-approved concentration for the product.[16,26]

Cyclic boron-based molecules (benzoxaboroles). Advances in the incorporation of boron-containing molecules in medicinal chemistry required that researchers depart from the traditional path of synthesizing and screening only boronic acid-based molecules.[16–20] This new approach led to the development of cyclicized boron-based molecules, such as oxaboroles and benzoxaboroles, the latter progressing to be a major platform for new drug development, including multiple compounds applicable to dermatology (discussed in more detail below). The integration of a boron ring into the cyclic structure allowed for greater stability, physiological availability to the requisite site of action, development of some compounds with dissociation constants (pKa) within physiological range of pH, and an optimized balance of molecule reactivity and target selectivity to reduce off-target interactions without significant loss of the desired therapeutic activity.[16–20] Through molecular modifications of certain benzoxaborole compounds, organoboron chemists are capable of producing small boron-based molecules that are highly stable, demonstrate effective target binding capacity and selectivity, and exhibit optimal physical properties that allow for access to the required anatomic site of the disease state. This was achieved with tavaborole (formerly AN2690), a benzoxaborole compound with a unique mode of action against dermatophytes and several other fungi (broad spectrum antifungal activity) and characteristics that allow for favorable penetration into and permeation through human nail plate and maintenance of antifungal activity in the presence of keratin.[27] Tavaborole was submitted to the FDA in 2013 for approval for the topical treatment of toenail onychomycosis.[27]
Benzoxaboroles have also been developed that inhibit phosphodiesterase-4 (PDE-4) (AN2728; AN2898) with various research studies demonstrating inhibition of various pro-inflammatory cytokines (potential application for psoriasis and atopic dermatitis), inhibition of leucyl-tRNA synthetase with activity against multiple fungal organisms (tavaborole; AN2718) and Gram-negative bacteria (AN3365), inhibition of HCV NS3 protease (potential application for hepatitis C infection), and antiprotozoal activity against Trypanosoma brucei (SCYX-7158; others).[16–20,28] The latter is a promising advance that may provide effective therapy for African sleeping sickness, a disorder that is endemic in Saharan Africa with tens of thousands of people infected annually and is associated with severe morbidity and death.[28]

Boron-Containing Compounds Under Development for Dermatologic Indications
Most of the boron-based molecules that are under development for indications related to dermatology fall under the benzoxaborole class of compounds. As discussed above, tavaborole has been submitted to the FDA for the topical treatment of onychomycosis with the New Drug Application (NDA) accepted by the agency as sufficiently complete for review and consideration for FDA approval (Business Wire press release, Anacor Pharmaceuticals, October 2013). Two PDE4 inhibitors are in the Phase II evaluation process with potential application for psoriasis and atopic dermatitis. Others are being evaluated as antibiotic or antifungal agents. Table 3 lists several compounds under evaluation for dermatological use with accompanying information that has been reported on the activity and properties of these molecules.

Despite the slow development of new therapeutic drug classes and novel compounds in dermatology, some researchers are focusing on development of new compound scaffolds. Advances in technologies and other developments in medicinal chemistry, and the vision and scientific dedication to further evaluate previously overlooked or misunderstood classes of compounds, have opened up novel pathways of drug development research. Despite prior unfounded perceptions of potential toxicities, and with the availability of new advances in synthetic organoboron chemistry, research of boron-based medicinal compounds has re-emerged. The incorporation of boron into a wide variety of small molecules allows for interaction with several therapeutic target sites on key functional proteins.
This research approach has provided a platform of unique boron-based compounds with potential for therapeutic application in many different disease states. Many of these compounds are in progressive phases of clinical drug development for skin diseases including fungal infections, atopic dermatitis, and psoriasis. Tavaborole, a benzoxaborole compound, has been submitted under an NDA to the FDA for topical treatment of onychomycosis. This agent exhibits a unique mode of action, specifically the inhibition of the editing domain of leucyl-tRNA synthetase with good relative selectivity for the fungal enzyme. Tavaborole exhibits antifungal activity against dermatophytes and several other fungi.
The versatility of several boron-based compounds to modifications that optimize physiochemical and pharmacological characteristics that conform to specific therapeutic needs has been central to the successful screening of many diverse compounds. Due to the variety of compounds and their versatility, different boron-based compounds have been found to interact with and inhibit specific functional proteins involved in different disease states and/or microbial pathogens. In dermatology, several preclinical and clinical studies have been completed with boron-based compounds, including tavaborole for topical treatment of onychomycosis and phosphodiesterase-4 inhibitors for atopic dermatitis and psoriasis. Additional research including clinical studies will further define the best indications and the efficacy and safety profiles of individual boron-based compounds. Importantly, this research approach provides a diverse platform of many interesting and promising medicinal compounds with potential uses in many areas of medicine, including dermatology.

1.     Eaglstein WH, Cash KR, Corcoran GR. Challenges encountered in dermatologic drug development. Actas Dermosifiliogr. 2009;100(Suppl 1):86–91.
2.    Ehrenberger HE, Joshi T. Dermatology clinical trials and drug development. Dermatol Nursing. 2003;15(5).
3.    Svensson L, Røpke MA, Norsgaard H. Psoriasis drug discovery: methods for evaluation of potential drug candidates. Expert Opin Drug Discov. 2012;7:49–61.
4.    Eaglstein WH. The FDA drug approval process. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy, 3rd ed. Philadelphia: Elsevier-Saunders; 2013: 41–45.
5.    Leyden JJ, Del Rosso JQ, Baum E, et al. The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. J Clin Aesthet Dermatol. 2014 (accepted for publication).
6.    Magel GD, Haitz KA, Lapolla WJ, et al. Systemic antiviral agents. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy, 3rd ed. Philadelphia: Elsevier-Saunders; 2013: 121–128.
7.    Patton TJ, Ferris LK. Systemic retinoids. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy, 3rd ed. Philadelphia: Elsevier-Saunders; 2013: 252–258.
8.    Bhutani T, Lee CS, Koo JYM. Cyclosporine. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy, 3rd ed. Philadelphia: Elsevier-Saunders; 2013: 199–202.
9.    FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. Accessed on July 26, 2013.
10.    Gupta AK. Systemic antifungal agents. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy, 3rd ed. Philadelphia: Elsevier-Saunders; 2013: 98–120.
11.    Kim S, Michaels BD, Kim GKK. Systemic antibacterial agents. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy, 3rd ed. Philadelphia: Elsevier-Saunders; 2013: 61–95.
12.    Del Rosso JQ, Leyden JJ. Status report on antibiotic resistance: implications for the dermatologist. Dermatol Clin. 2007;25(2): 127–132.
13.    Rosen T. Antibiotic resistance: an editorial review with recommendations. J Drugs Dermatol. 2011;10(7):724–733.
14.    Leyden JJ, Del Rosso JQ, Webster, GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Dermatol Clin. 2009;27(1):1–15.
15.    Del Rosso JQ. Cephalosporins in dermatology. Clin Dermatol. 2003;21(1):24–32.
16.    Baker SJ, Ding CZ, Akama T, et al. Therapeutic potential of boron-containing compounds. Future Med Chem. 2009;1(7): 1275–1288.
17.    Ciaravino V, Plattner J, Chanda A. An assessment of genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013;54:338–346.
18.    Akama T, Baker SJ, Zhang Y-K, et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Medic Chem Letters. 2009;19: 2129–2132.
19.    Baker SJ, Zhang Y-K, Akama T, et al. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690) for the potential treatment of onychomycosis. J Medic Chem. 2006;49(15):4447–4450.
20.    Akama T, Dong, D, Virtucio C, et al. Linking phenotype to kinase: identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency Rho kinase inhibitors. J Pharmacol Exp Ther. 2013;347:615–625.
21.    Groziak MP. Boron therapeutics on the horizon. Am J Ther. 2001;8:321–328.
22.    Yang W, Gao X, Wang B. Boronic acid compounds as potential pharmaceutical agents. Med Res Rev. 2003;23(3):346–368.
23.    Morandi S, Morandi F, Caselli E, et al. Structure-based optimization of cephalothin-analogue boronic acids as b-lactamase inhibitors. Bioorg Med Chem. 2008;16:1195–1205.
24.    Connolly BA, Sanford DG, Chiluwal AK, et al. Dipeptidyl boronic acid inhibitors of dipeptidyl peptidase IV: determination of potency and in vivo efficacy and safety. J Med Chem. 2008;51:6005–6013.
25.    Gronowitz S, Dahlgren T, Namtvedt J, et al. Antibacterial borazaro derivatives II: effect of substituents on the antibacterial activity of 5-arylsulfonyl-4-hydroxy-4,5-borazothieno[2,3-c]pyridines and 6-arylsulfonyl-7-hydroxy-7,6-borazothieno[3,2-c]pyridines. Acta Pharmaceutica Suecica. 1971;8(6):623–638.
26.    Byrn SR, Tishmack PA, Milton MJ, et al. Analysis of two commercially available bortezomib products: differences in assay of active agent and impurity profile. AAPS Pharm Sci Tech. 2011;12(2):461–467.
27.    Alley MRK, Baker S, Beutner K, et al. Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs. 2007;16(2):157–167.
28.    Jacobs RT, Nare B, Wang s, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 Human African Trypanosomiasis. PLOS Neglected Tropical Diseases. 2011;5(6):e1151. Published online 2011 June 28.
29.    Baker SJ, Hui X, Sanders V, et al. Nail penetration of AN2690: efficacy coefficient and effect on formulation. Poster presented at: European Society for Dermatologic Research, 36th Annual Meeting; Paris, France; September 7–9, 2006.
30.    Beutner K, Sanders V, Bullington R, et al. An open-label, multiple-dose study of the absorption and systemic pharmacokinetics of AN2690 applied as a 7.5% solution to all toenails of adult patients with moderate-to-severe onychomycosis. Poster presented at American Academy of Dermatology, 65th Annual Meeting; Washington, D.C.; February 2–6, 2007.
31.    Baker SJ, Sanders V, Plattner J, et al. Human nail penetration of AN2690, a new antifungal agent in development for the topical treatment of onychomycosis. Poster presented at: Perspectives in Percutaneous Penetration (PPP), 10th International Conference; Grande Motte, France; April 16, 2006.
32.    Hold KM, Bu W, Sanders V, et al. In vivo nail residence of AN2690, a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis. Poster presented at: American Academy of Dermatology, 65th Annual Meeting; Washington, D.C.; February 2–6, 2007.
33.    Zane LT, Pollak RA. Safety and efficacy of tavaborole (formerly AN2690), a novel boron-based molecule in Phase 2 trials for topical treatment of toenail onychomycosis. Poster presented at: National American Podiatric Medical Association Annual Scientific Meeting; Washington, D.C.; August 16–19, 2012.
34.    Anacor Pharmaceuticals to present pivotal phase 3 data of tavaborole for the topical treatment of toenail onychomycosis. Acquire Medie; press release; July 18, 2013.
35.    Akama T, Sanders V, Graves G, et al. Discovery of novel boron containing compounds as dual inhibitors of TNF? anf IL-23 release. Poster presented at: World Congress of Inflammation; Tokyo, Japan; July 6–10, 2009.
36.    Wigger-Alberti W, Zane LT. Dermal tolerability and preliminary efficacy of AN2728 and A2898, novel boron-based small molecules, in the treatment of psoriasis. Poster presented at: Annual Meeting of the European Society for Dermatologic Research; Barcelona, Spain; September 7–10, 2011.
37.    Zane LT, Tom WL, Chanda S, et al. Safety, pharmacokinetics and efficacy of AN2728 ointment, 2% in a phase 2 study of adolescents with mild-to-moderate atopic dermatitis. Poster presented at: IID 2013; Edinburgh, Scotland; May 8–11, 2013.
38.    Ip EY, Baker SJ, Hold KM, et al. Skin penetration and anti-inflammatory activity of AN2728, a novel oxaborole. Poster presented at: American Academy of Dermatology, 65th Annual Meeting; Washington, D.C.; February 2–6, 2007.